Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 800 results for "pdufa"

AEterna Zentaris: The Bear Case In Front Of The November 5th PDUFA
Seeking Alpha

AEterna Zentaris: The Bear Case In Front Of The November 5th P...

Summary There has been significant analysis of the bull case for AEterna Zentaris (AEZS), but there has not been significant work on the financial issues supporting the bear position. The company's significant cash burn and many past dilutions ... Seeking Alpha, 19 hours ago

1 images for "pdufa"

Seeking Alpha, 17 hours ago

FDA extends Natpara PDUFA date

To screen ETFs by asset class, performance, yield and more, check out the ETF Hub.
 Seeking Alpha1 week ago Natpara PDUFA date approaches  Seeking Alpha1 week ago PDUFA date approaches for Gilead Hep C combo  Seeking Alpha3 weeks ago October 29, 2014 Approval Letter - TRUMENBA  U.S. Food and Drug Administration16 hours ago

PDUFA date approaches for Xiaflex label expansion

The FDA's PDUFA date for reviewing Auxilium Pharmaceuticals' (AUXL +1.9%) sBLA requesting approval of Xiaflex (collagenase clostridium histolyticum) for the treatment of two Dupuytren's contracture cords concurrently is October 20. Xiaflex is ...
 Seeking Alpha2 weeks ago PDUFA date approaches for Lymphoseek expanded label  Seeking Alpha3 weeks ago

PDUFA Action Date for Natpara® BLA Extended Three Months to January 24, 2015

 Securities Technology Monitor1 week ago PDUFA Action Date for Natpara BLA Extended Three Months to January 24, 2015  FirstWord Pharma1 week ago PDUFA Action Date for Natpara(r) BLA Extended Three Months to Janua...  Finwin1 week ago NPS Pharmaceuticals : PDUFA Action Date for Natpara® BLA Extended Three Months to January 24, 2015  4 Traders1 week ago
[x]  

NPS Pharmaceuticals (NPSP) Says FDA Pushes Back PDUFA Date to Jan. 24

Visit StreetInsider.com at http://www.streetinsider.com/news.php-st=p&id=9937623 for the
 Crawford Financial Planning1 week ago
[x]  

Theravance's (THRX) CEO Mike Aguiar on Q3 2014 Results - Earnings Call Transcript

Operator Ladies and gentlemen, good afternoon. At this time, I would like to welcome everyone to the Theravance Conference Call. During the presentation all participants will be in a listen-only mode. A question-and-answer session will follow the ...
 Seeking Alpha5 hours ago Alkermes' (ALKS) CEO Rich Pops on Q3 2014 Results - Earnings Call Transcript  Seeking Alpha1 day ago Pfizer (PFE) Earnings Report: Q3 2014 Conference Call Transcript  TheStreet.com1 day ago Pfizer's (PFE) CEO Ian Read on Q3 2014 Results - Earnings Call Transcript  Seeking Alpha2 days ago

ONO PHARMACEUTICAL : Phase 2 Objective Response Rates and Survival Data for Opdivo (nivolumab) in Heavily Pre-treated Advanced Squamous Cell Non-Small Cell Lung Cancer to be Presented at the 2014 Chicago Multidisciplinary Symposium on Thoracic Oncology(11

Phase 2 Objective Response Rates and Survival Data for Opdivo (nivolumab) in Heavily Pre-treated Advanced Squamous Cell Non-Small Cell Lung Cancer to be Presented at the 2014 Chicago Multidisciplinary Symposium on Thoracic Oncology (PRINCETON, ...
 4 Traders5 hours ago Bristol-Myers Squibb Company (BMY)'s Opdivo Wows In Phase 2 Lung Cancer Study 10/30/2014  ClinicSpace14 hours ago Phase 2 data for Opdivo (nivolumab) to be presented  European Pharmaceutical Review17 hours ago Phase 2 Objective Response Rate and Survival Data for Opdivo (nivolumab) in Heavily Pre-treated Advanced Squamous Cell Non-Small Cell Lung Cancer to be Presented at the 2014 Chicago Multidisciplinary Symposium on Thoracic Oncology  Nasdaq19 hours ago
[x]  

Avanir Pharmaceuticals to publish AVP-825 phase III study results in the journal 'Headache'

Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the publication of results from TARGET, a pivotal phase III study evaluating the efficacy and safety of AVP-825 22mg in the January 2015 issue of Headache (Early access is now available).
 News-Medical.Net6 hours ago Avanir Pharmaceuticals Announces Publication of Pivotal Phase III Results from AVP-825 Acute Migraine Study in the Journal "Headache"  Pettinga Financial Advisors12 hours ago
[x]  
Securities Technology Monitor

Impax Announces R&D Reorganization Designed to Yield Process Improvements and Efficiencies

HAYWARD, Calif., Oct. 30, 2014 /PRNewswire/ -- Impax Laboratories, Inc. (NASDAQ: IPXL) today announced a reorganization of its research and development (R&D) organizations and a prioritization of the project portfolios within the generic and brand ...
 TickerTech.com12 hours ago
[x]  

United Therapeutics Sells Off On Good News - Why I Bought That Dip

Summary United Therapeutics sold off from a high level after reporting a strong quarter that marginally missed consensus sales expectations. More important is the good news that the company foreshadowed on its conference call. UTHR is an ...
 Seeking Alpha12 hours ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less